| Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors RA Beckman, LM Weiner, HM Davis Cancer 109 (2), 170-179, 2007 | 425 | 2007 |
| Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors I Krop, T Demuth, T Guthrie, PY Wen, WP Mason, P Chinnaiyan, ... Journal of clinical oncology 30 (19), 2307-2313, 2012 | 349 | 2012 |
| On the fidelity of DNA replication: manganese mutagenesis in vitro RA Beckman, AS Mildvan, LA Loeb Biochemistry 24 (21), 5810-5817, 1985 | 317 | 1985 |
| Cancers exhibit a mutator phenotype: clinical implications LA Loeb, JH Bielas, RA Beckman Cancer research 68 (10), 3551-3557, 2008 | 262 | 2008 |
| Interaction of the RNA‐binding domain of the hnRNP C proteins with RNA. M Görlach, M Wittekind, RA Beckman, L Mueller, G Dreyfuss The EMBO journal 11 (9), 3289-3295, 1992 | 257 | 1992 |
| Genetic instability in cancer: theory and experiment RA Beckman, LA Loeb Seminars in cancer biology 15 (6), 423-435, 2005 | 185 | 2005 |
| Solution structure of horse heart ferricytochrome c and detection of redox-related structural changes by high-resolution 1H NMR PX Qi, RA Beckman, AJ Wand Biochemistry 35 (38), 12275-12286, 1996 | 167 | 1996 |
| Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors SA Mullamitha, NC Ton, GJM Parker, A Jackson, PJ Julyan, C Roberts, ... Clinical Cancer Research 13 (7), 2128-2135, 2007 | 163 | 2007 |
| Identification of a local anesthetic binding site in nicotinic post-synaptic membranes isolated from Torpedo marmorata electric tissue EK KRODEL, RA BECKMAN, JB COHEN Molecular pharmacology 15 (2), 294-312, 1979 | 160 | 1979 |
| On the fidelity of DNA replication. Effect of the next nucleotide on proofreading. TA Kunkel, RM Schaaper, RA Beckman, LA Loeb Journal of Biological Chemistry 256 (19), 9883-9889, 1981 | 132 | 1981 |
| A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid … F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ... Clinical Cancer Research 17 (19), 6304-6312, 2011 | 130 | 2011 |
| A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid … F Atzori, J Tabernero, A Cervantes, L Prudkin, J Andreu, ... Clinical Cancer Research 17 (19), 6304-6312, 2011 | 130 | 2011 |
| A roadmap to using historical controls in clinical trials–by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG) M Ghadessi, R Tang, J Zhou, R Liu, C Wang, K Toyoizumi, C Mei, ... Orphanet Journal of Rare Diseases 15 (1), 1-19, 2020 | 125 | 2020 |
| Integrating predictive biomarkers and classifiers into oncology clinical development programmes RA Beckman, J Clark, C Chen Nature Reviews Drug Discovery 10 (10), 735-748, 2011 | 125 | 2011 |
| Alpha-v integrins as therapeutic targets in oncology JA Nemeth, MT Nakada, M Trikha, Z Lang, MS Gordon, GC Jayson, ... Cancer investigation 25 (7), 632-646, 2007 | 119 | 2007 |
| A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer M Gore, A Oza, G Rustin, J Malfetano, H Calvert, D Clarke-Pearson, ... European Journal of Cancer 38 (1), 57-63, 2002 | 114 | 2002 |
| Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer RA Beckman, GS Schemmann, CH Yeang Proceedings of the National Academy of Sciences 109 (36), 14586-14591, 2012 | 111 | 2012 |
| Efficiency of carcinogenesis with and without a mutator mutation RA Beckman, LA Loeb Proceedings of the National Academy of Sciences 103 (38), 14140-14145, 2006 | 109 | 2006 |
| Efficiency of carcinogenesis with and without a mutator mutation RA Beckman, LA Loeb Proceedings of the National Academy of Sciences 103 (38), 14140-14145, 2006 | 109 | 2006 |
| Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy … A Forero‐Torres, JR Infante, D Waterhouse, L Wong, S Vickers, ... Cancer medicine 2 (6), 925-932, 2013 | 107 | 2013 |
Lawrence A. LoebUniversity of Washington在 u.washington.edu 的电子邮件经过验证
